Trellus Health PLC ( (GB:TRLS) ) has shared an announcement.
Trellus Health PLC has announced a business update highlighting its collaboration with Johnson & Johnson to pilot the Trellus Elevate program for patients with inflammatory bowel disease in the US. The company has extended its cash runway to October 2025 and concluded the enrollment phase of a B2B2C agreement with a US national health plan, showing positive outcomes for enrolled members. Trellus Health is focusing on expanding its pharmaceutical partnerships to enhance patient support and clinical trials, demonstrating the potential value of its resilience-based platform.
More about Trellus Health PLC
Trellus Health PLC is a healthcare company specializing in value-based innovative solutions and services for chronic conditions. It offers Trellus Elevate®, a digital platform integrating data analytics with resilience programs to manage complex chronic conditions, particularly focusing on gastrointestinal issues like Inflammatory Bowel Disease (IBD). The company aims to empower patients through self-management solutions, leading to reduced hospitalizations and emergency room visits. Founded by Mount Sinai faculty members, Trellus Health collaborates with pharmaceutical partners to enhance patient support and clinical trial success.
YTD Price Performance: 390.38%
Average Trading Volume: 8,342,062
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £4.12M
Learn more about TRLS stock on TipRanks’ Stock Analysis page.